Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 29 of 37, showing 5 Applications out of 181 total, starting on record 141, ending on 145

# Protocol No Study Title Investigator(s) & Site(s)

141.

ECCT/15/12/05   Post-discharge Malaria Chemoprevention(PMC) study
    Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-centre, parallel-group, two-arm randomised placebo controlled superiority trial   
Principal Investigator(s)
1. Titus Kwambai
2. Simon Kariuki
Site(s) in Kenya
1. Siaya County Referral Hospital (Siaya county)
2. Homa Bay County Referral Hospital (Homa Bay county)
3. Migori County Referral Hospital (Migori county)
4. Busia County Referral Hospital (Busia county)
 
View

142.

ECCT/15/12/02   The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial
    A Multi Centre, Open label, Randomized Clinical Trial, Comparing HIV incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone Acetate, Levernogestrel (LNG) implant and Copper Intrauterine Devices (IUD).   Short Title : The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial   
Principal Investigator(s)
1. Prof Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI-RCTP Study center , Lumumba
 
View

143.

ECCT/15/11/01   A5264
    A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy   versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of   Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS)   
Principal Investigator(s)
1. Dr. Victor Otieno Mudhune
Site(s) in Kenya
1. KEMRI CDC (Kisumu county)
 
View

144.

ECCT/15/08/01   Rifapentine During Intensive Phase TB Treatment
     Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: a randomized, open-label, controlled, phase 3 clinical trial   
Principal Investigator(s)
1. Elisha Ochieng Okeyo
Site(s) in Kenya
KEMRICDC, KISUMU, KENYA
 
View

145.

ECCT/15/06/03   DolutegrAvir With NRTIs as second-line treatment (DAWNING)
    A Phase 3b, randomised, open-label study of the antiviral activity and safety of dolutegravir compared to lopinavir/ritonavir both administered with dual nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected adult subjects with treatment failure on first line therapy   
Principal Investigator(s)
1. Dr. Evans Inyangala Amukoye
2. Dr. Maricianah Atieno Onono
Site(s) in Kenya
1. Center for Respiratory Diseases Research, CRDR, KEMRI, Nairobi (Nairobi City county)
2. KEMRI-Research Care and Training Program (RCTP), Family AIDS Care and Education Services (FACES), Lumumba health centre (Kisumu county)
 
View